Abstract: The present disclosure discloses a method for preparing a lysate, from a combination of umbilical cord blood (UCB) and maternal blood (MB) derived platelets by obtaining platelet-rich plasma via sedimentation processes and then mixing platelet-rich plasmas so obtained. The present disclosure further discloses a combination of umbilical cord blood and maternal blood platelet lysate (UCB+MB PL), and the PL so obtained shows greater efficacy as cell and tissue culture media supplement over and above its individual components, umbilical cord blood platelet lysate (UCB PL) and maternal blood platelet lysate (MB PL) and especially over foetal bovine serum (FBS). Moreover, the method of the present disclosure provides an economic, environment friendly, ethical and efficacious method to reach a cell and tissue culture supplement with far-reaching therapeutic applications.

Abstract: The present disclosure discloses a method for preparing a lysate, from a combination of umbilical cord blood (UCB) and maternal blood (MB) derived platelets by obtaining platelet-rich plasma via sedimentation processes and then mixing platelet-rich plasmas so obtained. The present disclosure further discloses a combination of umbilical cord blood and maternal blood platelet lysate (UCB+MB PL), and the PL so obtained shows greater efficacy as cell and tissue culture media supplement over and above its individual components, umbilical cord blood platelet lysate (UCB PL) and maternal blood platelet lysate (MB PL) and especially over foetal bovine serum (FBS). Moreover, the method of the present disclosure provides an economic, environment friendly, ethical and efficacious method to reach a cell and tissue culture supplement with far-reaching therapeutic applications.

Abstract: The present disclosure provides a method for obtaining osteoblast cell-mixture which can be used for transplantation of osteoblast cells in a subject. The present disclosure further discloses a method for delivering osteoblast cells into a subject. The method for obtaining osteoblast cell-mixture as disclosed herein is devoid of any additives like calcium chloride and aprotinin. The method for delivering osteoblast cells as disclosed herein provides bone regeneration in the subject.

Abstract: The present disclosure discloses a method for isolating osteoprogenitors like mesenchymal stem cells (MSCs) from clotted bone marrow and culturing with a platelet lysate obtained from a combination of discarded umbilical cord blood and maternal blood platelet-rich plasma (instead of non-human animal origin serum) and differentiating those MSCs into osteoblasts under sterile conditions for further therapeutic applications. Particularly, the present disclosure relates to a method for expansion of osteoblasts to make cell therapy products with a fixed cell dose, which are characterized and later cryopreserved for future use through its cell culture process. Further, the present disclosure relates to identifying specific gene expression from MSCs to osteoblast formation, an in-vitro differentiation process that replicates the in-vivo bone remodelling system.

Abstract: A process of preparing buccal epithelial cell suspension and cystoscopically implanting the cell suspension in the defect site of the adult human urethra.

Abstract: A process for the preparation of chondrocyte cell suspension and its use in defect site of knee or ankle or shoulder or wrist or elbow or hip of subject.